Association Between Thyroid Hormone Levels and Advanced Liver Fibrosis in Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease

被引：13

作者：

Du, Jing ^{[1
]}

Chai, Sanbao ^{[1
]}

Zhao, Xin ^{[1
]}

Sun, Jianbin ^{[1
]}

Zhang, Xiaomei ^{[1
]}

Huo, Lili ^{[2
]}

机构：

[1] Peking Univ Int Hosp, Dept Endocrinol, 1 Life Garden Rd Zhongguancun Life Sci Garden, Beijing, Peoples R China

[2] Beijing Jishuitan Hosp, Dept Endocrinol, Beijing, Peoples R China

来源：

DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY | 2021年 / 14卷

关键词：

diabetes mellitus; advanced fibrosis; thyroid hormone; non-alcoholic fatty liver disease; RISK; EPIDEMIOLOGY; MANAGEMENT; STAGE;

D O I：

10.2147/DMSO.S313503

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Purpose: To evaluate the effects of serum thyroid hormone levels on advanced liver fibrosis in cases with NAFLD (non-alcoholic fatty liver disease) and T2DM (type 2 diabetes mellitus). Patients and Methods: A total of 1422 cases with T2DM who were admitted to Peking University International Hospital between December 2014 and October 2019 were retrospectively analyzed. Standard anthropometry as well as clinical and laboratory evaluation were performed on all patients. Abdominal ultrasonography was performed to diagnose NAFLD. NFS (NAFLD fibrosis score) was used to identify advanced fibrosis in patients with T2DM and NAFLD. Results: In cases with T2DM and NAFLD, the serum FT3 level in cases with advanced fibrosis was lower than that in those without advanced fibrosis (4.79 +/- 0.89 vs 4.28 +/- 1.19, P < 0.05), and significant difference was not found in serum levels of FT4 and TSH between cases with advanced fibrosis and those without advanced fibrosis (P > 0.05). The incidence of advanced fibrosis declined as the rise of serum FT3 levels (P-trend < 0.05). Besides, FT3 (OR, 0.492; 95% CI, 0.384-0.631) was noted as a factor influencing advanced fibrosis in cases with T2DM and NAFLD (P<0.05). Conclusion: In cases with T2DM and NAFLD, the incidence of advanced fibrosis is negatively correlated with serum FT3 levels, and a low FT3 level is an independent risk factor of advanced fibrosis.

引用

页码：2399 / 2406

页数：8

共 33 条

[1] Thyroid hormones inhibit TGF-β signaling and attenuate fibrotic responses [J].

Alonso-Merino, Elvira ;

Martin Orozco, Rosa ;

Ruiz-Llorente, Lidia ;

Martinez-Iglesias, Olaia A. ;

Pedro Velasco-Martin, Juan ;

Montero-Pedrazuela, Ana ;

Fanjul-Rodriguez, Luisa ;

Contreras-Jurado, Constanza ;

Regadera, Javier ;

Aranda, Ana .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (24) :E3451-E3460

[2] Thyroid Function and the Risk of Nonalcoholic Fatty Liver Disease: The Rotterdam Study [J].

Bano, Arjola ;

Chaker, Layal ;

Plompen, Elisabeth P. C. ;

Hofman, Albert ;

Dehghan, Abbas ;

Franco, Oscar H. ;

Janssen, Harry L. A. ;

Murad, Sarwa Darwish ;

Peeters, Robin P. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (08) :3204-3211

[3] Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action [J].

Bril, Fernando ;

Cusi, Kenneth .

DIABETES CARE, 2017, 40 (03) :419-430

[4] The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases [J].

Chalasani, Naga ;

Younossi, Zobair ;

Lavine, Joel E. ;

Charlton, Michael ;

Cusi, Kenneth ;

Rinella, Mary ;

Harrison, Stephen A. ;

Brunt, Elizabeth M. ;

Sanyal, Arun J. .

HEPATOLOGY, 2018, 67 (01) :328-357

[5] Ceramides - Lipotoxic Inducers of Metabolic Disorders [J].

Chaurasia, Bhagirath ;

Summers, Scott A. .

TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2015, 26 (10) :538-550

[6] Free triiodothyronine is associated with the occurrence and remission of nonalcoholic fatty liver disease in euthyroid women [J].

Chen, Peizhu ;

Hou, Xuhong ;

Wei, Li ;

Feng, Liang ;

Zhong, Lichang ;

Jiao, Lei ;

Wang, Hongmei ;

Bao, Yuqian ;

Jia, Weiping .

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2019, 49 (04)

[7] Increased Risk of Mortality by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis [J].

Dulai, Parambir S. ;

Singh, Siddharth ;

Patel, Janki ;

Soni, Meera ;

Prokop, Larry J. ;

Younossi, Zobair ;

Sebastiani, Giada ;

Ekstedt, Mattias ;

Hagstrom, Hannes ;

Nasr, Patrik ;

Stal, Per ;

Wong, Vincent Wai-Sun ;

Kechagias, Stergios ;

Hultcrantz, Rolf ;

Loomba, Rohit .

HEPATOLOGY, 2017, 65 (05) :1557-1565

[8] Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial [J].

Harrison, Stephen A. ;

Bashir, Mustafa R. ;

Guy, Cynthia D. ;

Zhou, Rong ;

Moylan, Cynthia A. ;

Frias, Juan P. ;

Alkhouri, Naim ;

Bansal, Meena B. ;

Baum, Seth ;

Neuschwander-Tetri, Brent A. ;

Taub, Rebecca ;

Moussa, Sam E. .

LANCET, 2019, 394 (10213) :2012-2024

[9] Metabolomic analysis shows differential hepatic effects of T2 and T3 in rats after short-term feeding with high fat diet [J].

Iannucci, Liliana F. ;

Cioffi, Federica ;

Senese, Rosalba ;

Goglia, Fernando ;

Lanni, Antonia ;

Yen, Paul M. ;

Sinha, Rohit A. .

SCIENTIFIC REPORTS, 2017, 7

[10] Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease [J].

Ipsen, David Hojland ;

Lykkesfeldt, Jens ;

Tveden-Nyborg, Pernille .

CELLULAR AND MOLECULAR LIFE SCIENCES, 2018, 75 (18) :3313-3327

← 1 2 3 4 →